Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

被引:324
|
作者
Eich, Hans Theodor
Diehl, Volker
Goergen, Helen
Pabst, Thomas
Markova, Jana
Debus, Juergen
Ho, Anthony
Doerken, Bernd
Rank, Andreas
Grosu, Anca-Ligia
Wiegel, Thomas
Karstens, Johann Hinrich
Greil, Richard
Willich, Normann
Schmidberger, Heinz
Doehner, Hartmut
Borchmann, Peter
Mueller-Hermelink, Hans-Konrad
Mueller, Rolf-Peter
Engert, Andreas [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
POSITRON-EMISSION-TOMOGRAPHY; INTERNATIONAL PROGNOSTIC SCORE; NODE RADIOTHERAPY; STAGE-I; DISEASE; CYCLES; PROGRESSION; RADIATION; SUPERIOR; THERAPY;
D O I
10.1200/JCO.2010.29.8018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. Patients and Methods Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 x 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT. Results With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy. Conclusion Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.
引用
收藏
页码:4199 / 4206
页数:8
相关论文
共 50 条
  • [1] Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) Randomized HD11 Trial
    Eich, H. T.
    Mueller, R. P.
    Diehl, V.
    Goergen, H.
    Mueller-Hermelink, H.
    Schmidt, B.
    Grosu, A.
    Karstens, J.
    Willich, N.
    Engert, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S1 - S1
  • [2] Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial
    Borchmann, Peter
    Diehl, Volker
    Goergen, Helen
    Mueller, Horst
    Mueller, Rolf Peter
    Eich, Hans T.
    Mueller-Hermelink, Hans Konrad
    Herrmann, Richard
    Markova, Jana
    Ho, Anthony D.
    Hiddemann, Wolfgang
    Doerken, Bernd
    Greil, Richard
    Engert, Andreas
    BLOOD, 2009, 114 (22) : 299 - 300
  • [3] Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin Lymphoma (HL): Final analysis of the German Hodgkin Study Group (GHSG) HD11 trial
    Borchmann, P.
    Diehl, V
    Goergen, H.
    Mueller, H.
    Mueller, R. P.
    Eich, H.
    Mueller-Hermelink, K.
    Herrmann, R.
    Markova, J.
    Ho, A.
    Hiddemann, W.
    Doerken, B.
    Greil, R.
    Engert, A.
    ONKOLOGIE, 2010, 33 : 125 - 125
  • [4] COMBINED MODALITY TREATMENT WITH INTENSIFIED CHEMOTHERAPY AND DOSE-REDUCED INVOLVED FIELD RADIOTHERAPY IN PATIENTS WITH EARLY UNFAVOURABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD11 TRIAL
    Engert, A.
    Borchmann, P.
    Diehl, V.
    Goergen, H.
    Mueller, H.
    Mueller, R.
    Eich, H.
    Mueller-Hermelink, H.
    Herrmann, R.
    Markova, J.
    Ho, A.
    Hiddemann, W.
    Doerken, B.
    Greil, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 167 - 167
  • [5] Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma:: An analysis of the German Hodgkin Study Group
    Eich, Hans Theodor
    Engenhart-Cabillic, Rita
    Hansemann, Katja
    Lukas, Peter
    Schneeweiss, Angelika
    Seegenschmiedt, Heinrich
    Skripnitchenko, Roman
    Staar, Susanne
    Willich, Normann
    Mueller, Rolf-Peter
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (05): : 1419 - 1424
  • [6] Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma - An analysis of the German Hodgkin's Study Group (GHSG)
    Eich, H. T.
    Engenhart-Cabillic, R.
    Hansemann, K.
    Lukas, P.
    Seegenschmiedt, H.
    Staar, S.
    Willich, N.
    Mueller, R. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S535 - S535
  • [7] Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
    von Tresckow, Bastian
    Pluetschow, Annette
    Fuchs, Michael
    Klimm, Beate
    Markova, Jana
    Lohri, Andreas
    Kral, Zdenek
    Greil, Richard
    Topp, Max S.
    Meissner, Julia
    Zijlstra, Josee M.
    Soekler, Martin
    Stein, Harald
    Eich, Hans T.
    Mueller, Rolf P.
    Diehl, Volker
    Borchmann, Peter
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 907 - 913
  • [8] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
    Engert, A
    Schiller, P
    Josting, A
    Herrmann, R
    Koch, P
    Sieber, M
    Boissevain, F
    de Wit, M
    Mezger, J
    Dühmke, E
    Willich, N
    Müller, RP
    Schmidt, BF
    Renner, H
    Müller-Hermelink, HK
    Pfistner, B
    Wolf, J
    Hasenclever, D
    Löffler, M
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608
  • [9] Recent interim analysis of the HD11 trial of the GHSG: Intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma.
    Diehl, V
    Brillant, C
    Engert, A
    Mueller, RP
    Eich, HT
    Mueller-Hermelink, K
    Herrmann, R
    Markova, J
    Ho, A
    Hiddemann, W
    Doerken, B
    Greil, R
    Josting, A
    Pfistner, B
    BLOOD, 2005, 106 (11) : 240A - 241A
  • [10] Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma:: an analysis from the German Hodgkin Study Group
    Klimm, B.
    Eich, H. T.
    Haverkamp, H.
    Lohri, A.
    Koch, P.
    Boissevain, F.
    Trenn, G.
    Worst, P.
    Duehmke, E.
    Mueller, R. P.
    Mueller-Hermelink, K.
    Pfistner, B.
    Diehl, V.
    Engert, A.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 357 - 363